Please ensure Javascript is enabled for purposes of website accessibility

Why MannKind Corporation Stock Is Sinking Today

By George Budwell - Dec 18, 2017 at 3:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Afrezza's commercial launch continues to underwhelm.

What happened

Shares of MannKind Corp. (NASDAQ: MNKD) fell by as much as 11% on moderate volume in early-morning trading today. The culprit? The biotech's stock appears to be reacting to the disappointing scrip numbers for its inhaled insulin product, Afrezza, in early December. The key concern is that MannKind appears destined to miss consensus again on revenue when it reports fourth-quarter earnings next year -- that is, unless something dramatic happens in the last few weeks of December.

A graph of a negative trend drawn on a chalkboard

Image source: Getty Images.

So what

Despite a favorable label change that breathed new life into the company earlier this year, Afrezza still isn't selling well enough to change MannKind's outlook in the near -- or long -- term. MannKind will probably have to dilute shareholders yet again in early 2018, simply to keep itself afloat. Afrezza, after all, is projected to bring in around a mere $25.7 million in sales next year, while the company burned through over $23 million last quarter alone.

Now what

To be frank, MannKind's day of reckoning seems close at hand. The company can't get Afrezza to gain traction in the marketplace, and it's running out of resources to throw at the effort. In fact, MannKind is at the stage where it's probably going to need to dilute shareholders every other quarter simply to keep up its doors open -- that's not a winning scenario for shareholders. Heading into the end of the year, MannKind comes across as a strong candidate to sell for tax purposes.

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.